Valsartan detailed information
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 95% |
| Elimination half-life | 6 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C24H29N5O3 |
| Molar mass | 435.519 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
For patient information, click here
Valsartan is an angiotensin II receptor antagonist, acting on the AT1 subtype. In the U.S., valsartan is indicated for treatment of high blood pressure, of congestive heart failure (CHF), and post-myocardial infarction (MI). It is marketed by Novartis under the trade name Diovan®. In 2005, Diovan® was prescribed more than 12 million times in the United States. A study released by the Journal of Clinical Investigation in 2007 found some efficacy in the use of Valsartan in the treatment and prevention of Alzheimer's disease although such use is considered to be highly experimental.[1]
Administration
Oral tablets, containing 40 mg (scored), 80 mg, 160 mg or 320 mg of valsartan. Usual dosage ranges from 40–320 mg daily.
In some markets available as a Hard Gelatin Capsule, containing 40mg, 80mg, or 160mg of valsartan.
Diovan HCT® contains a combination of Valsartan and hydrochlorothiazide but, unlike Diovan®, is only indicated for hypertension, not for CHF or post-MI.
Side effects
Most commonly, headache and dizziness.
References
- ↑ "Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease." http://content.the-jci.org/articles/view/31547 . 2007.
External links
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Angiotensin II receptor antagonists
- Novartis
- Drugs